Collaborations

Helsinn Healthcare SA – Pracinostat Worldwide License

In August 2016, we entered into an exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, for pracinostat in acute myeloid leukemia, myelodysplastic syndrome and other potential indications. Under the agreement, Helsinn holds a worldwide exclusive license to develop, manufacture and commercialize pracinostat, and is primarily responsible for funding its global development and commercialization. Pursuant to the agreement, we received payments of $20.0 million and we are eligible to receive up to $444 million in potential regulatory and sales-based milestones, along with royalty payments on the net sales of pracinostat, which, in the U.S., are tiered and begin in the mid-teens.